News Center

位置：

Honors Announcement

Group News

Media Reports

A Case from Shijiazhuang Sihua Pharmaceutical Group Selected as a Typical Example of Quality Improvement and Brand Building by the Ministry of Industry and Information Technology

Category:

Honors Announcement

发布时间：2025-01-12

【概要描述】 At the start of the new year, more good news has emerged. On January 10, the Ministry of Industry and Information Technology released the list of exemplary cases for quality improvement and brand development in the industrial and information technology sectors for 2024. Among them, Shijiazhuang Sihua Pharmaceutical Group’s submission, “Application of the ‘21235’ Risk Management Model Based on Parameter-Based Release,” was selected as a model case in the category of quality innovation and technological application, fully demonstrating the company’s remarkable achievements in quality enhancement.

At the start of the new year, more good news has emerged. On January 10, the Ministry of Industry and Information Technology released the list of exemplary cases for quality improvement and brand development in the industrial and information technology sectors for 2024. Among them, Shijiazhuang Sihua Pharmaceutical Group’s submission, “Application of the ‘21235’ Risk Management Model Based on Parameter-Based Release,” was selected as a model case under the category of quality innovation and technological application, fully demonstrating the company’s remarkable achievements in quality enhancement.

The 2024 Selection of Typical Cases for Quality Improvement and Brand Building is an annual priority initiative launched by the Ministry of Industry and Information Technology to further enhance quality management capabilities in the industrial and information technology sectors, accelerate the innovation and application of quality technologies, improve product reliability, cultivate more “Made in China” brands with international influence, and strengthen the summarization of best practices and the promotion of outstanding cases. The call for typical cases focuses on four key areas: quality management capability, innovation and application of quality technologies, reliability enhancement, and brand building. This year, a total of 100 exemplary cases of quality improvement and brand building in the industrial and information technology sectors were selected.

As a key pillar enterprise in Shijiazhuang’s biopharmaceutical industry, Shijiazhuang Sihua Pharmaceutical has consistently upheld its original aspiration of “producing high-quality medicines for the people.” In the manufacturing of its flagship infusion preparations, the company adopts a forward-looking approach, benchmarking against internationally advanced quality-management concepts and technologies. It has actively explored and established a “21235” risk-control model based on parameter-based release: creating two sets of standards, employing one tool, institutionalizing two safeguards, strengthening three supporting elements, and optimizing five processes. By leveraging automated, information-driven, and intelligent quality-management methods, the company has achieved high-level, integrated, closed-loop quality management across the entire value chain—from product R&D to commercial production—while continuously improving its quality-management system. This approach has effectively promoted the synergistic development of quality management and technological innovation, steadily enhancing the company’s core competitiveness and accelerating the upgrade of its flagship products toward the mid- to high-end segments of the value chain. As a result, the company has played a leading and exemplary role in driving high-quality development within the industry.

A relevant official from the group stated that, going forward, the company will take its inclusion as a typical case in the national initiative for quality enhancement and brand development as an opportunity to further leverage its pivotal role in quality innovation, continuously implement the strategy of strengthening the enterprise through branding, consolidate the foundation of quality, build competitive advantages for its brands, and consistently highlight the leading impact of its brands. In doing so, the company aims to deliver new achievements in innovation and value creation, thereby contributing to a new leap forward in the high-quality development of our city’s biopharmaceutical industry.

Keywords:

Three projects of Guangxiang Pharmaceutical, a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, have been selected as major science and technology special projects and science and technology program projects of Cangzhou City.

Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Awarded the “Integrity Unit” Title by Huanghua City